

Krystexxa® (pegloticase)

When requesting Krystexxa® (pegloticase), the individual requiring treatment must be diagnosed with an FDA-approved indication or approved compendial use and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

Krystexxa® (pegloticase) is indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

Approved Off-label Compendial Uses

- Nephrolithiasis
- Gouty nephropathy

Coverage Guidelines

For all indications, an individual meets all of the following criteria:

- Krystexxa is prescribed by or in consultation with a rheumatologist or a nephrologist
- For re-authorization, an individual is responding to therapy with evidence of serum uric acid level less than 6 mg/dL with continued treatments.

For chronic gout (initial authorization):

- An individual has current symptoms of gout (e.g., gout flares, gout tophus, gouty arthritis) **AND**
- An individual has had an inadequate response (i.e., serum uric acid level remains greater than 6 mg/dL) following a 3-month trial of at least ONE of the following agents: allopurinol, Uloric, or a uricosuric agent (e.g., probenecid, fenofibrate, losartan), **OR**
- Patient has a contraindication or had a intolerance to a trial of allopurinol

For nephrolithiasis/gouty nephropathy (initial authorization):

- An individual has had an inadequate response (i.e., serum uric acid level greater than 6 mg/dL) following a 3-month trial of allopurinol or Uloric **OR**
- An individual has contraindication or intolerance to a trial of allopurinol.

Approval duration (initial): 6 months

Approval duration (renewal): 12 months

Dosing Recommendation

The recommended dose is 8 mg given as an intravenous infusion every 2 weeks.

References

1. Krystexxa™ injection for intravenous infusion [prescribing information]. East Brunswick, NJ: Savient Pharmaceuticals; July 2018.
2. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. *JAMA*. 2011;306(7):711-720.
3. Shen Z, Rowlings C, Kerr B, et al. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. *Drug Des Devel Ther*. 2015;9:3423-3434
4. Gout. Centers for Disease Control and Prevention [Web site]. Last reviewed January 28, 2019. Available at: <http://www.cdc.gov/arthritis/basics/gout.html>. Accessed on April 22, 2019.
5. Edwards NL. Treatment-failure gout: a moving target. *Arthritis Rheum*. 2008;58(9):2587-2590.
6. Marasini B, Massarotti M. What rheumatologists should know about gout and cardiovascular disease. *J Rheumatol*. 2009;36(4):854-855.
7. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res*. 2012;64:1431-1446.
8. Food and Drug Administration. FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat). Updated February 21, 2019. Accessed on April 22, 2019. Available at: <https://www.fda.gov/Drugs/DrugSafety/ucm631182.htm>.
9. Uloric [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals; February 2019.
10. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*. 2017;76(1):29-42.
11. Wiederkehr MR, Moe OW. Uric Acid Nephrolithiasis: a systemic metabolic disorder. *Clin Rev Bone Miner Metab*. 2011;9(3-4):207-217.